ClinicalTrials.gg
RecruitingNCT06380751EvoPAR-BR01Updated Oct 30, 2026

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

A Phase 3 interventional study of Saruparib (AZD5305) and Camizestrant in Advanced Breast Cancer, sponsored by AstraZeneca. Recruiting at 306 sites in 29 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.
Updated Oct 30, 2026Site recruiting status changed2 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
788
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing AZD9833 in Breast Neoplasms — 6 open to participants now, 10 under way, 7 of them phase 3. AZD9833 · Breast Neoplasms.

Planned enrollment
4th of 17
788 · median 150
Started
2024
with 1 other
Phase 3
7 of 17
4 open now
Registered
12th of 17
by date
Lead sponsor
15 of 17
AstraZeneca

Among the 17 studies testing AZD9833 in Breast Neoplasms, this one is the 4th largest by planned enrollment, is one of 2 that started in 2024, is one of 7 in phase 3, and was the 12th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

6 of the 17 studies testing AZD9833 in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About AZD9833

AZD9833: first FDA approval 2026 (ETCAMAH), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing AZD9833 in Breast Neoplasms, or all of them as a file.
02

Study summary

The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+, 2+/ ISH non-amplified) advanced breast cancer

Read the detailed description

Approximately 4680 participants will be screened to achieve approximately 788 participants randomised to study intervention.

Participants will be randomised in a 2:2:1:2 ratio to one of the following intervention groups:

  • Arm 1: saruparib (AZD5305) plus camizestrant
  • Arm 2: Physician's choice CDK4/6i plus physician's choice ET
  • Arm 3: Physician's choice CDK4/6i plus camizestrant
  • Arm 4: Saruparib (AZD5305) plus physician's choice ET

Treatment continues until BICR-confirmed disease progression, unacceptable toxicity occurs, or the participant withdraws consent.

03

Conditions studied

  • Advanced Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult females, pre/peri-menopausal and/or , and adult males
  • or cytologically documented diagnosis of HR-positive, -negative breast cancer
  • Advanced breast cancer with either locally advanced disease not amenable to curative treatment or disease
  • performance status of 0 or 1 with no deterioration over the previous 2 weeks
  • FFPE tumour tissue from each participant
  • Documented germline tumour loss of function mutation in BRCA1, BRCA2, or PALB2
  • Adequate organ and marrow function

Exclusion criteria

Exclusion Criteria:

  • Participants with history of MDS/AML or with features suggestive of MDS/AML
  • Participants with any known predisposition to bleeding
  • Any history of persisting severe cytopenia
  • Any evidence of severe or uncontrolled systemic diseases or active uncontrolled infections
  • nausea and vomiting, chronic GI disease, inability to swallow the formulated product, or previous significant bowel resection
  • History of another primary
  • Persistent toxicities ( Grade ≥ 2) caused by previous anti-cancer therapy excluding alopecia
  • Spinal cord compression, , carcinomatous meningitis, or
  • Evidence of active and uncontrolled and/or
  • Evidence of active and uncontrolled infection
  • Active tuberculosis infection
  • Cardiac criteria, including history of arrythmia and cardiovascular disease
  • Concurrent exogenous reproductive hormone therapy or non-topical hormonal therapy for non-cancer-related conditions
  • Major surgical procedure or significant traumatic injury within 4 weeks of the first dose of study intervention or an anticipated need for major surgery during the study
  • Palliative radiotherapy with a limited field of radiation within 2 weeks or with wide field of radiation or to more than 30% of the bone marrow within 4 weeks before the first dose of study treatment
  • Prior treatment with systemic anti-cancer therapy for locoregionally recurrent or disease is not permitted, apart from treatment with ET for up to 28 days total before randomisation
  • Prior treatment within 28 days with blood product support or growth factor support
  • Any systemic concurrent anti-cancer treatment
  • Concomitant use of the following types of medications or herbal supplements within 21 days or at least 5 half-lives of randomisation:

    1. Strong and moderate inducers/inhibitors
    2. Sensitive CYP2B6 substrates
    3. Substrates of CYP2C9 and/or CYP2C19 which have a narrow therapeutic index, eg, warfarin (and other coumarin-derived vitamin K antagonist anticoagulants) and phenytoin.
  • Concomitant use of drugs that are known to prolong and have a known risk of TdP
  • Systemic use of atropine
  • The following exclusion criteria apply to treatments administered for early breast cancer:

    1. Disease progression ≤ 84 days following the last dose of or adjuvant chemotherapy
    2. Disease progression ≤ 1 year (365 days) from the last dose of treatment with a PARPi and/or platinum agent for early breast cancer
    3. Disease progression ≤ 1 year (365 days) from the last dose with a CDK4/6i in the adjuvant setting
    4. Disease progression ≤ 1 year (365 days) from the last dose of an oral SERD including camizestrant.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
788 participants (estimated)

Study arms

  • Experimental
    Arm 1: saruparib (AZD5305) plus camizestrant

    participants will receive saruparib (AZD5305) orally and camizestrant orally

    Drug: Saruparib (AZD5305) · Drug: Camizestrant

  • Active comparator
    Arm 2: Physician's choice CDK4/6i plus physician's choice ET

    agents are indicated below and should follow local guidelines: * Physician's Choice CDK4/6i: * abemaciclib orally, or * ribociclib orally, or * palbociclib orally. * Physician's Choice ET: * fulvestrant intramuscularly, or * One of the following AIs: * letrozole orally, or * anastrozole orally, or * exemestane orally

    Drug: Abemaciclib · Drug: Ribociclib · Drug: Palbociclib · Drug: Fulvestrant · Drug: Letrozole · Drug: Anastrozole · Drug: Exemestane

  • Experimental
    Arm 3: Physician's choice CDK4/6i plus camizestrant

    participants will receive camizestrant orally. Agents for CDK4/6i treatment are indicated above and should follow local guidelines

    Drug: Camizestrant · Drug: Abemaciclib · Drug: Ribociclib · Drug: Palbociclib

  • Experimental
    Arm 4: Saruparib (AZD5305) plus physician's choice ET

    participants will receive Saruparib (AZD5305) plus -Physician's Choice ET: * fulvestrant intramuscularly, or * One of the following AIs: * letrozole orally, or * anastrozole orally, or * exemestane orally

    Drug: Saruparib (AZD5305) · Drug: Fulvestrant · Drug: Letrozole · Drug: Anastrozole · Drug: Exemestane

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (Arm 1 vs arm 2)

    PFS is defined as time from randomisation until progression per RECIST v1.1 as assessed by BICR, or death due to any cause.

    Time frame: Up to approximately 64 months

Secondary outcomes

  1. Progression-Free Survival (arm 4 vs 2, arm 1 vs 3, arm 3 vs 2, arm 4 vs 1)

    PFS is defined as time from randomisation until progression per RECIST v1.1 as assessed by BICR, or death due to any cause.

    Time frame: Up to approximately 64 months

  2. Overall Survival (arm 1 vs 2, arm 4 vs 2, arm 1 vs 3, arm 3 vs 2, arm 4 vs 1)

    OS is defined as the time from randomisation until the date of death due to any cause.

    Time frame: Up to approximately 88 months

  3. Progression Free Survival 2 (arm 1 vs 2, arm 4 vs 2, arm 1 vs 3, arm 3 vs 2, arm 4 vs 1)

    PFS2 is defined as the time from randomisation to the earliest of the progression event (following the initial investigator-assessed progression), after first subsequent therapy, or death.

    Time frame: Up to approximately 64 months

  4. Time to chemotherapy (arm 1 vs 2, arm 4 vs 2, arm 1 vs 3, arm 3 vs 2, arm 4 vs 1)

    Time to chemotherapy is defined as time from randomisation until the start date of the first subsequent chemotherapy treatment after discontinuation of randomised treatment (censoring participants who died prior to initiation of chemotherapy).

    Time frame: Up to approximately 64 months

  5. Objective Response Rate (arm 1 vs 2, arm 4 vs 2, arm 1 vs 3, arm 3 vs 2, arm 4 vs 1)

    ORR is defined as the proportion of participants who have a complete or partial response, as determined by BICR per RECIST v1.1.

    Time frame: Up to approximately 64 months

  6. Duration of Response (arm 1 vs 2, arm 4 vs 2, arm 1 vs 3, arm 3 vs 2, arm 4 vs 1)

    DoR is defined as the time from the date of first documented response until date of documented progression per RECIST v1.1 as assessed by BICR, or death due to any cause.

    Time frame: Up to approximately 64 months

  7. Participant-reported tolerability (arm 1 vs 2, arm 4 vs 2, arm 1 vs 3, arm 3 vs 2, arm 4 vs 1)

    Proportion of all dosed participants reporting different levels of severity of diarrhoea as measured by the diarrhoea single item (EORTC IL237/IL239/IL240) and different levels of severity of abdominal pain as measured by the abdominal pain single item (EORTC IL237/IL239/IL240).

    Time frame: Up to approximately 64 months

  8. Time to deterioration in patient-reported global health status/QoL as measured by the global health status/QoL scale within the EORTC quality of life questionnaire (QLQ) (arm 1 vs 2, arm 4 vs 2, arm 1 vs 3, arm 3 vs 2, arm 4 vs 1)

    This scale includes 2 items asking participants to report overall health and overall quality of life in the past week. Both items are measured on a 6-point verbal rating scale ranging from Very Poor to Excellent. Single item scores are averaged to calculate a subscale score that is transformed to range from 0 to 100, where higher scores indicate better global health status/QoL.

    Time frame: Up to approximately 64 months

  9. Change from baseline in patient-reported global health status/QoL as measured by the global health status/QoL scale within the EORTC quality of life questionnaire (QLQ) (arm 1 vs 2, arm 4 vs 2, arm 1 vs 3, arm 3 vs 2, arm 4 vs 1)

    This scale includes 2 items asking participants to report overall health and overall quality of life in the past week. Both items are measured on a 6-point verbal rating scale ranging from Very Poor to Excellent. Single item scores are averaged to calculate a subscale score that is transformed to range from 0 to 100, where higher scores indicate better global health status/QoL.

    Time frame: Up to approximately 64 months

  10. Plasma concentrations of saruparib (AZD5305)

    Time frame: Up to approximately 64 months

  11. Plasma concentrations of camizestrant

    Time frame: Up to approximately 64 months

  12. Samples will be used to develop companion diagnostics by analyzing their performance characteristics and calculate their consistency with clinical trial assays used for enrolment onto the study.

    Samples will be tested by a CDx to confirm BRCA1/2 and PALB2 gene mutation status

    Time frame: Up to approximately 64 months

07

Study locations

242 of 306 sites recruiting
  • Research Site
    Gilbert, Arizona 85234, United States
    Recruiting
  • Research Site
    Fountain Valley, California 92708, United States
    Recruiting
  • Research Site
    Glendale, California 91206, United States
    Recruiting
  • Research Site
    Los Angeles, California 90089, United States
    Recruiting
  • Research Site
    Newport Beach, California 92663, United States
    Recruiting
  • Research Site
    Aurora, Colorado 80045, United States
    Recruiting
  • Research Site
    Grand Junction, Colorado 81501, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Hollywood, Florida 33021, United States
    Recruiting
  • Research Site
    Jacksonville, Florida 32224, United States
    Recruiting
  • Research Site
    Orlando, Florida 32806, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Orlando, Florida 32806, United States
    Not yet recruiting
  • Research Site
    Arlington Heights, Illinois 60005, United States
    Recruiting
  • Research Site
    Chicago, Illinois 60611, United States
    Recruiting
  • Research Site
    Evanston, Illinois 60201, United States
    Recruiting
  • Research Site
    Park Ridge, Illinois 60068, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Schaumburg, Illinois 60173, United States
    Not yet recruiting
  • Research Site
    Urbana, Illinois 61801, United States
    Recruiting
  • Research Site
    Winfield, Illinois 60190, United States
    Recruiting
  • Research Site
    Indianapolis, Indiana 46227, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Louisville, Kentucky 40207, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Baltimore, Maryland 21201, United States
    Recruiting
  • Research Site
    Silver Spring, Maryland 20902, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Silver Spring, Maryland 20904, United States
    Recruiting
  • Research Site
    Boston, Massachusetts 02215, United States
    Recruiting
  • Research Site
    Boston, Massachusetts 02215, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Dearborn, Michigan 48126, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Detroit, Michigan 48202, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Royal Oak, Michigan 48073, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Royal Oak, Michigan 48073, United States
    Recruiting
  • Research Site
    Rochester, Minnesota 55905, United States
    Recruiting
  • Research Site
    Saint Joseph, Missouri 64507, United States
    Recruiting
  • Research Site
    Springfield, Missouri 65804, United States
    Recruiting
  • Research Site
    St Louis, Missouri 63110, United States
    Not yet recruiting
  • Research Site
    Camden, New Jersey 08103, United States
    Recruiting
  • Research Site
    New Brunswick, New Jersey 08901, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Brooklyn, New York 11220, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Mineola, New York 11501, United States
    Recruiting
  • Research Site
    New Hyde Park, New York 11042, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    New York, New York 10016, United States
    Recruiting
  • Research Site
    New York, New York 10028, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    New York, New York 10065, United States
    Recruiting
  • Research Site
    Shirley, New York 11967, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Stony Brook, New York 11790, United States
    Recruiting
  • Research Site
    The Bronx, New York 10469, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Westbury, New York 11590, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Hershey, Pennsylvania 17033, United States
    Recruiting
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • Research Site
    Pittsburgh, Pennsylvania 15212, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Pittsburgh, Pennsylvania 15215, United States
    Recruiting
  • Research Site
    West Columbia, South Carolina 29169, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Chattanooga, Tennessee 37404, United States
    Recruiting
  • Research Site
    Nashville, Tennessee 37203, United States
    Recruiting
  • Research Site
    Houston, Texas 77030, United States
    Not yet recruiting
  • Research Site
    Houston, Texas 77030, United States
    Recruiting
  • Research Site
    Houston, Texas 77054, United States
    Recruiting
  • Research Site
    San Antonio, Texas 78240, United States
    Recruiting
  • Research Site
    Midlothian, Virginia 23114, United States
    Not yet recruiting
  • Research Site
    Norfolk, Virginia 23502, United States
    Recruiting
  • Research Site
    Tacoma, Washington 98405, United States
    Recruiting
  • Research Site
    Morgantown, West Virginia 26506, United States
    Recruiting
  • Research Site
    Milwaukee, Wisconsin 53215, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Ciudad Autónoma Buenos Aires, 1125, Argentina
    Recruiting
  • Research Site
    Ciudad de Buenos Aires, 1015, Argentina
    Recruiting
  • Research Site
    Ciudad de Buenos Aires, C1280AEB, Argentina
    Recruiting
  • Research Site
    Córdoba, 5008, Argentina
    Recruiting
  • Research Site
    Rosario, S2000KZE, Argentina
    Recruiting
  • Research Site
    Salta, A4400EMI, Argentina
    Recruiting
  • Research Site
    San Miguel de Tucumán, 4000, Argentina
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Darlinghurst, 2010, Australia
    Recruiting
  • Research Site
    Darlinghurst, 2139, Australia
    Recruiting
  • Research Site
    Malvern, 3144, Australia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Melbourne, VIC 3000, Australia
    Recruiting
  • Research Site
    Graz, 8036, Austria
    Recruiting
  • Research Site
    Innsbruck, 6020, Austria
    Recruiting
  • Research Site
    Linz, 4010, Austria
    Recruiting
  • Research Site
    Vienna, 1090, Austria
    Recruiting
  • Research Site
    Cachoeira de Itapemirim, 29308-055, Brazil
    Recruiting
  • Research Site
    Curitiba, 80060-900, Brazil
    Recruiting
  • Research Site
    Fortaleza, 60336-045, Brazil
    Recruiting
  • Research Site
    Goiânia, 74000-000, Brazil
    Recruiting
  • Research Site
    Jaú, 17210-120, Brazil
    Recruiting
  • Research Site
    Porto Alegre, 91350-200, Brazil
    Recruiting
  • Research Site
    Ribeirão Preto, 14049-901, Brazil
    Recruiting
  • Research Site
    Salvador, 41253-190, Brazil
    Recruiting
  • Research Site
    São Paulo, 01509-900, Brazil
    Recruiting
  • Research Site
    São Paulo, 03102-002, Brazil
    Recruiting
  • Research Site
    Plovdiv, 4002, Bulgaria
    Recruiting
  • Research Site
    Sofia, 1527, Bulgaria
    Recruiting
  • Research Site
    Stara Zagora, 6003, Bulgaria
    Recruiting
  • Research Site
    Vratsa, 3000, Bulgaria
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Toronto, Ontario M5G 2M9, Canada
    Not yet recruiting
  • Research Site
    Greenfield Park, Quebec J4V 2G9, Canada
    Not yet recruiting
  • Research Site
    Montreal, Quebec H2X 0A9, Canada
    Not yet recruiting
  • Research Site
    Montreal, Quebec H3T 1E2, Canada
    Not yet recruiting
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
    Not yet recruiting
  • Research Site
    Saskatoon, Saskatchewan S7N 4H4, Canada
    Not yet recruiting
  • Research Site
    Toronto, M4N 3M5, Canada
    Not yet recruiting
  • Research Site
    Providencia, 7500994, Chile
    Recruiting
  • Research Site
    Recoleta, 8420391, Chile
    Recruiting
  • Research Site
    Santiago, 8330034, Chile
    Recruiting

Showing the first 100 of 306 sites across 29 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Dec 2029, 64 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 64 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2024
First posted
Apr 24, 2024
StartActual
Aug 1, 2024
Primary completionEst.
Dec 18, 2029
CompletionEst.
Dec 30, 2031
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed. 5 sites changed recruiting status (3 now recruiting, 1 now not yet recruiting, …)
Show 5 sites
  • Research Site · Baltimore, United StatesNot yet recruiting→Recruiting
  • Research Site · Houston, United StatesWithdrawn→Not yet recruiting
  • Research Site · Kunming, ChinaNot yet recruiting→Recruiting
  • Research Site · Hong Kong, Hong KongNot yet recruiting→Recruiting
  • Research Site · Zaragoza, SpainNot yet recruiting→Withdrawn
Show 2 added (2 United States)
  • Research Site · Boston, United States
  • Research Site · Midlothian, United States
Show 2 removed
  • Research Site · Richmond, United States
  • Research Site · Ratchathewi, Thailand
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    2 sites added, 2 sites removed. 5 sites changed recruiting status (3 now recruiting, 1 now not yet recruiting, …)
    Show 5 sites
    • Research Site · Baltimore, United StatesNot yet recruiting→Recruiting
    • Research Site · Houston, United StatesWithdrawn→Not yet recruiting
    • Research Site · Kunming, ChinaNot yet recruiting→Recruiting
    • Research Site · Hong Kong, Hong KongNot yet recruiting→Recruiting
    • Research Site · Zaragoza, SpainNot yet recruiting→Withdrawn
    Show 2 added (2 United States)
    • Research Site · Boston, United States
    • Research Site · Midlothian, United States
    Show 2 removed
    • Research Site · Richmond, United States
    • Research Site · Ratchathewi, Thailand
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06380751
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 24, 2024
Start date
Aug 1, 2024
Primary completion
Dec 18, 2029 (estimated)
Completion
Dec 30, 2031 (estimated)
Last update
Oct 30, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: AZD5305 · AZD9833 · Letrozole

Start the discussion